{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:49:47Z","timestamp":1776232187415,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the autoantibody profile, including myositis-associated autoantibodies (MAAs) and myositis-specific autoantibodies (MSAs), and their influence on outcomes of rituximab (RTX) treatment in patients with IIM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included data from patients with idiopathic inflammatory myositis (IIM) who met at least one of the following criteria: Bohan and Peter, ACR\/EULAR 2017, and European Neuromuscular Center (ENMC) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-three patients, 72% of whom were female, were included. Among them, 32.1% had a clinical diagnosis of dermatomyositis, 35.8% antisynthetase syndrome (ASS), 15.3% overlap syndrome, 11.3% polymyositis, and 5.7% had immune-mediated necrotizing myopathy. RTX was used in 49% of the patients, and nearly half of them (46%) had ASS. Remission was achieved in 77%, a partial response was observed in 11.5%, and unresponsiveness\/active disease was observed in 11.5% of patients receiving RTX. Relapse was lower, and mortality tended to be lower in patients receiving RTX. In multivariate analysis, MSA positivity was associated with remission in those receiving RTX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our study, RTX was safe and effective in patients with IIM who had an inadequate response or severe disease at admission. Furthermore, the presence of MSAs may predict a favourable response to RTX treatment in patients with IIM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf097","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:09:35Z","timestamp":1760011775000},"page":"407-414","source":"Crossref","is-referenced-by-count":0,"title":["Presence of myositis-specific autoantibodies may predict favourable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8165-7650","authenticated-orcid":false,"given":"Emin","family":"O\u011fuz","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Istinye University Bah\u00e7e\u015fehir Liv Hospital , Istanbul ,","place":["Turkey"]},{"name":"Division of Rheumatology, Department of Internal Medicine, Van District Training and Research Hospital , Van ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0942-0947","authenticated-orcid":false,"given":"Nevzat","family":"Koca","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Istinye University Vadi Liv Hospital , Istanbul ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1788-3837","authenticated-orcid":false,"given":"Murat","family":"Bekta\u015f","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Istanbul Ayd\u0131n University , Istanbul ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2026041500570298000_ref1","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026041500570298000_ref2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2026041500570298000_ref3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromusc Disord: NMD"},{"key":"2026041500570298000_ref4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, the Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscular disorders: NMD"},{"key":"2026041500570298000_ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026041500570298000_ref6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"2026041500570298000_ref7","doi-asserted-by":"publisher","first-page":"e2243799","DOI":"10.1001\/jamanetworkopen.2022.43799","article-title":"Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with Polyangiitis","volume":"5","author":"Pu\u00e9chal","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026041500570298000_ref8","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026041500570298000_ref9","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis","volume":"22","author":"Duxbury","year":"2013","journal-title":"Lupus"},{"key":"2026041500570298000_ref10","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026041500570298000_ref11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026041500570298000_ref12","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026041500570298000_ref13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2026041500570298000_ref14","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026041500570298000_ref15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2169\/internalmedicine.44.527","article-title":"Autoantibodies to aminoacyl-tRNA synthetases","volume":"44","author":"Hirakata","year":"2005","journal-title":"Intern Med (Tokyo, Japan)"},{"key":"2026041500570298000_ref16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/rheumatology\/kead671","article-title":"Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centred retrospective cohort study","volume":"64","author":"Tang","year":"2025","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026041500570298000_ref17","doi-asserted-by":"crossref","first-page":"1051609","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"key":"2026041500570298000_ref18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00296-023-05302-9","article-title":"Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease","volume":"43","author":"Zeki\u0107","year":"2023","journal-title":"Rheumatol Int"},{"key":"2026041500570298000_ref19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.31138\/mjr.30.3.186","article-title":"Interstitial lung disease in anti-Synthetase syndrome","volume":"30","author":"Kourkouni","year":"2019","journal-title":"Mediterranean J Rheumatol"},{"key":"2026041500570298000_ref20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/rheumatology\/key450","article-title":"Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study","volume":"58","author":"Leclair","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026041500570298000_ref21","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3899\/jrheum.190505","article-title":"Rituximab and cyclophosphamide in antisynthetase syndrome\u2013related interstitial lung disease: an observational retrospective study","volume-title":"The Journal of Rheumatology","author":"Langlois","year":"2020"},{"key":"2026041500570298000_ref22","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"},{"key":"2026041500570298000_ref23","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026041500570298000_ref24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","author":"Aggarwal","year":"2014"},{"key":"2026041500570298000_ref25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"D\u00f6rner","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2026041500570298000_ref26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.autrev.2017.11.015","article-title":"Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and\/or malignant hematological disorders","volume":"17","author":"Tudesq","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2026041500570298000_ref27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/RHU.0000000000001855","article-title":"Antineutrophil cytoplasmic antibody-associated casculitis and COVID-19: the clinical course and prognosis of 15 patients from a tertiary care Center","volume":"28","author":"\u0130nce","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2026041500570298000_ref28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"key":"2026041500570298000_ref29","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2026041500570298000_ref30","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1007\/s10067-024-07178-x","article-title":"Validation of the 2018 (new) ENMC classification criteria for Dermatomyositis in Chinese patients with idiopathic inflammatory myopathies","volume":"43","author":"Zhang","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026041500570298000_ref31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026041500570298000_ref32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"2026041500570298000_ref33","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1445-5994.2010.02164.x","article-title":"Clinical heterogeneity and prognostic features of south Australian patients with anti-synthetase autoantibodies","volume":"41","author":"Dugar","year":"2011","journal-title":"Intern Med J"},{"key":"2026041500570298000_ref34","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology (Oxford, England)"},{"key":"2026041500570298000_ref35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf097\/64573419\/roaf097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/407\/64573419\/roaf097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/407\/64573419\/roaf097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:57:11Z","timestamp":1776229031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/3\/407\/8279883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,9]]},"published-print":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf097","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,10,9]]}}}